C4 Therapeutics (CCCC) Operating Income (2019 - 2026)

C4 Therapeutics' Operating Income history runs 8 years deep, the most recent figure standing at -$27.8 million for Q1 2026.

• In Q1 2026, Operating Income rose 4.73% year-over-year to -$27.8 million; the TTM figure through Mar 2026 stood at -$113.8 million (up 2.33% YoY), while the FY2025 annual figure was -$115.2 million, up 3.67% from the prior year.
• Operating Income for Q1 2026 stood at -$27.8 million, down from -$23.1 million in the prior quarter.
• The five-year high for Operating Income was -$21.4 million in Q2 2024, with the low at -$38.3 million in Q4 2022.
• The 5-year median for Operating Income is -$31.4 million (2022), against an average of -$31.2 million.
• The sharpest annual moves came in 2022 and 2024: Operating Income tumbled 151.02% in 2022, then jumped 42.92% in 2024.
• C4 Therapeutics' Operating Income stood at -$38.3 million in 2022, then gained by 2.26% to -$37.4 million in 2023, then retreated by 0.75% to -$37.7 million in 2024, then surged by 38.62% to -$23.1 million in 2025, then declined by 20.05% to -$27.8 million in 2026.
• Business Quant data shows CCCC's Operating Income at -$27.8 million in Q1 2026, -$23.1 million in Q4 2025, and -$34.4 million in Q3 2025.